摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

dodecyl hydrogen sulfate;(R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol | 106525-44-4

中文名称
——
中文别名
——
英文名称
dodecyl hydrogen sulfate;(R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol
英文别名
——
dodecyl hydrogen sulfate;(R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol化学式
CAS
106525-44-4
化学式
C32H50N2O6S
mdl
——
分子量
590.8
InChiKey
DIGLODHVPMVAEM-DSXUQNDKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.9
  • 重原子数:
    41
  • 可旋转键数:
    16
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.66
  • 拓扑面积:
    118
  • 氢给体数:
    2
  • 氢受体数:
    8

文献信息

  • Pharmaceutical formulations comprising sodium laurylsulfate as bitterness masking agent
    申请人:Boehringer Ingelheim International GmbH
    公开号:EP1452177A1
    公开(公告)日:2004-09-01
    The present invention refers to a new bitterness masking agent for pharmaceutical formulations which are to be applied orally. It was found that certain pharmaceutically acceptable surfactants can mask the bitter taste of some bitter tasting pharmaceutically active compounds. The present invention in particular concerns epinastine or quinine comprising formulations.
    本发明涉及一种用于口服药物配方的新型苦味掩蔽剂。研究发现,某些药学上可接受的表面活性剂可以掩盖某些苦味药用活性化合物的苦味。本发明尤其涉及由依匹斯汀或奎宁组成的制剂。
  • [EN] PHARMACEUTICAL FORMULATIONS COMPRISING SODIUM LAURYLSULFATE AS BITTERNESS MASKING AGENT<br/>[FR] PREPARATIONS PHARMACEUTIQUES COMPRENANT DE NOUVEAUX AGENTS DE MASQUAGE DE GOUT AMER
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2004075900A2
    公开(公告)日:2004-09-10
    The present invention refers to a new bitterness masking agent for pharmaceutical formulations which are to be applied orally. It was found that certain pharmaceutically acceptable surfactants can mask the bitter taste of some bitter tasting pharmaceutically active compounds. The present invention in particular concerns epinastine or quinine comprising formulations.
查看更多